- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05230186
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienkontakt
- Name: Laurie Barefoot, APRN
- Telefonnummer: 857-399-9930
- E-Mail: Lbarefoot@tscan.com
Studieren Sie die Kontaktsicherung
- Name: Shrikanta Chattopadhyay, MD
- Telefonnummer: 857-399-9472
- E-Mail: Schattopadhyay@tscan.com
Studienorte
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90033
- Rekrutierung
- USC Norris Comprehensive Cancer Center
-
Kontakt:
- Xiomara Menendez, RN,
- Telefonnummer: 323-865-0212
- E-Mail: Xiomara.menendez@med.usc.edu
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70124
- Rekrutierung
- Ochsner Clinic Foundation
-
Hauptermittler:
- Marc Matrana, MD
-
Kontakt:
- Donnalee Trapani, CCRP, CRC
- Telefonnummer: 504-865-0212
- E-Mail: dtrapani@ochsner.org
-
Kontakt:
- Rafael Velasquezvalle, Sr. CRC
- Telefonnummer: 504-842-8170
- E-Mail: Rafael.velasquezvalle@ochsner.org
-
Unterermittler:
- Lyndsey Buckner Baiamonte, Ph.D
-
-
New Jersey
-
Morristown, New Jersey, Vereinigte Staaten, 07960
- Rekrutierung
- Atlantic Health System
-
Hauptermittler:
- Eric Whitman, MD
-
Kontakt:
- Maureen Nowakowski, RN
- Telefonnummer: 973-971-7111
- E-Mail: Maureen.nowakowski@atlantichealth.org
-
-
New York
-
New York, New York, Vereinigte Staaten, 10013
- Rekrutierung
- Advanced Oncology PC
-
Kontakt:
- Kin Lam, MD
- Telefonnummer: 212-941-9020
- E-Mail: kin.lam@rendrcare.com
-
Kontakt:
- Isabel Wong, RN
- Telefonnummer: 212-941-9020
- E-Mail: isabelwong2@gmail.com
-
Hauptermittler:
- Kin Lam, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
Cohort Legend: Cohort 1: On-Treatment Responder (Biopsy), Cohort 2: Pre and On-Treatment (Biopsy), Cohort 3: On-Treatment Responder (Surgery), Cohort 4: Post-Treatment Vitiligo, Cohort 5: Post-Treatment Responder (Frozen)
- Study Cohorts 1,2,3 and 5: Known or suspected diagnosis of non-hematological malignancy.
- Age 18 years at time of diagnosis.
- Research Biopsy Study Cohorts 1 and 2: ECOG performance status 0-2.
- Ability to understand and willingness to sign an informed consent document.
- Research Biopsy Study Cohorts 1,2,3 and 5: Patients must be eligible for or currently receiving treatment with immune checkpoint inhibitor (ICI) therapy as determined by the patient's treating oncologist. The treatment regimen may comprise more than one agent but must include at least one ICI drug. Examples of FDA-approved ICI drugs include pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq), avelumab (Bavencio), durvalumab (Imfinzi), cemiplimab (Libtayo), and ipilimumab (Yervoy). Immune-checkpoint inhibitors not on this list may also be used, provided they are FDA-approved.
- Research Biopsy Study Cohorts 1,2,3 and 5: Patients undergoing an on-treatment biopsy must show radiographic regression of one or more lesion, as assessed by the investigator.
- Research Biopsy Study Cohorts 1 and 2: Patients undergoing an on-treatment biopsy must have a cancer lesion that is amenable for biopsy under local anesthesia or moderate sedation per standard procedures. The tumor biopsy must have an acceptable clinical risk, as judged by the investigator.
- Research Biopsy Study Cohorts 1,2,4: Platelet count >50,000 prior to biopsy or per the service performing the biopsy.
- Research Biopsy Study Cohorts 1,2,4: Absolute neutrophil count >1500.
- Research Biopsy Study Cohorts 1,2,4: Must be able to safely hold anticoagulants for 5 days prior to biopsy.
- Research Biopsy Study Cohorts 1,2,4: Not receiving therapeutic anticoagulation at the time of the biopsy. Patients on therapeutic anticoagulation must be able to safely hold anticoagulation for the procedure with an acceptable risk, as judged by the investigator. Patients who are on anticoagulation for clinical reasons and deemed appropriate for biopsy must be OFF anticoagulation prior to biopsy as follows:
i. No warfarin (Coumadin) for 5 days. No low-molecular weight heparin (LMWH; e.g. dalteparin/ Fragmin, enoxaparin/ Lovenox) for 24 hours.
ii. No fondaparinux/ Arixtra for 48 hours. iii. Patients receiving alternative forms of anticoagulation not listed above (e.g., dabigatran, rivaroxaban, apixaban, edoxaban) should consult with the prescribing physician and the service performing the biopsy regarding safety and administration guidelines prior to biopsy. Bleeding risks with these agents should be considered when deciding on whether to perform the biopsy if for research purposes only.
Exclusion Criteria:
Cohort Legend: Cohort 1: On-Treatment Responder (Biopsy), Cohort 2: Pre and On-Treatment (Biopsy), Cohort 3: On-Treatment Responder (Surgery), Cohort 4: Post-Treatment Vitiligo, Cohort 5: Post-Treatment Responder (Frozen)
- Concurrent disease or condition that would make the patient inappropriate for study participation, or any serious medical or psychiatric disorder that would interfere with safety.
- Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
- Research Biopsy Study Cohorts 1,2,4: History of serious or life-threatening allergic reaction to local anesthetics (i.e., lidocaine, xylocaine).
- Pregnant women are excluded because there may be an increased risk to both mother and fetus in the setting of moderate sedation, which is required for biopsies of certain anatomic sites (e.g., liver, lung, bone). Also, ionizing radiation from CT-guided biopsies may pose a risk to the unborn fetus.
- Research Biopsy Study Cohorts 1,2,4: Active cardiac disease, defined as:
i. Uncontrolled or symptomatic angina within the past 3 months. ii. History of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, torsades de pointes). Atrial fibrillation with controlled ventricular response on treatment is not an exclusion.
iii. Myocardial infarction < 6 months from study entry. iv. Uncontrolled or symptomatic congestive heart failure. f. Any other condition, which in the opinion of the patient's treating oncologist or the physician performing the biopsy procedure, would make participation in this protocol unreasonably hazardous for the patient.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
On-Treatment Solid Tumor Responder (Tumor Biopsy)
Research tumor tissue biopsy collected at any one time point while responding to ICI therapy (radiographic regression of lesion).
Tumor biopsy and companion blood sample.
|
Research biopsy of solid tumor or sharing of excess tumor tissue during a planned surgical or biopsy procedure and a companion blood sample.
Andere Namen:
|
Pre and On-Treatment Solid Tumor Responder (Tumor Biopsy)
Tumor tissue collection prior to beginning ICI therapy (optional biopsy).
If and when there is a response to ICI therapy, a second research tumor tissue biopsy is collected.
Tumor biopsy and companion blood sample.
|
Research biopsy of solid tumor or sharing of excess tumor tissue during a planned surgical or biopsy procedure and a companion blood sample.
Andere Namen:
|
On-Treatment Solid Tumor Responder (Surgical Removal Tumor)
Collection of excess tumor tissue in patients who are responding to ICI therapy and are scheduled for Surgical resection of residual disease.
Excess tissue provided.
|
|
Post-Treatment of patients with Melanoma who develop vitiligo
Up to 5 patients treated for melanoma that develop vitiligo - Skin Tissue Biopsy obtained at any point in time from any skin site with vitiligo (selected sites only).
Tissue biopsy
|
Research biopsy of solid tumor or sharing of excess tumor tissue during a planned surgical or biopsy procedure and a companion blood sample.
Andere Namen:
|
On-Treatment Responder (Previously Frozen Tumor Tissue)
Previously Cryopreserved Tissue obtained from a Biobank or Tissue Repository, collected from patients when they were responding to ICI Therapy (clinical data required).
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Single Cell Sequencing
Zeitfenster: 3 years
|
Determine, through single-cell sequencing, the TCR repertoire of these tumor and blood samples to identify new targets.
|
3 years
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 200-04
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Solider Tumor, Erwachsener
-
Abramson Cancer Center at Penn MedicineAktiv, nicht rekrutierendAdolescent and Young Adult (AYA) KrebsüberlebendeVereinigte Staaten
-
St. Boniface HospitalHeart and Stroke Foundation of CanadaRekrutierungErnährung schlecht | Kardiovaskuläre Morbidität | Gebrechliches Syndrom älterer ErwachsenerKanada
-
Wake Forest University Health SciencesAbgeschlossenKritische Krankheit | Akuter Atemstillstand | ErwachsenensyndromVereinigte Staaten
-
Georgetown UniversityNoch keine RekrutierungPrädiabetes | Postmenopausal | Adolescent and Young Adult (AYA) Krebsüberlebende
-
Aadi Bioscience, Inc.RekrutierungFortgeschrittener solider Tumor | Tumor | Tumor, solideVereinigte Staaten
-
Second Xiangya Hospital of Central South UniversityRekrutierung
-
Central Hospital, Nancy, FranceAbgeschlossen
-
RemeGen Co., Ltd.AbgeschlossenMetastasierter solider Tumor | Lokal fortgeschrittener solider Tumor | Nicht resezierbarer solider TumorAustralien
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyRekrutierungSolider Tumor, Erwachsener | Refraktärer TumorVereinigte Staaten
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnbekanntFortgeschrittener solider Tumor oder hämatologischer TumorChina
Klinische Studien zur Tumor Biopsy
-
Zydolab - Institute of Cytology and Immune CytochemistryRuhr University of BochumAbgeschlossenGebärmutterhalsdysplasieDeutschland
-
University of Southern CaliforniaUniversidade do PortoRekrutierungMagenkrebs | Magendysplasie | Magen-MetaplasieVereinigte Staaten, Portugal
-
Cliniques universitaires Saint-Luc- Université...Université de LiègeRekrutierungMukoviszidose | BiomarkerBelgien
-
Aquyre Bioscience, IncBoston University; Fox Chase Cancer Center; Johnson & JohnsonRekrutierung
-
NeoDynamics ABRekrutierungBrustkrebsVereinigtes Königreich
-
Modarres HospitalAbgeschlossen
-
Emory UniversityAbgeschlossenBewertung und Vergleich von zwei chirurgischen Methoden zur Behandlung von Brustkrebs im FrühstadiumBrustkrebs | Neoplasien der Brust | Brusttumore | Neubildungen, Brust | Brustkrebs | Krebs der Brust | Menschliches MammakarzinomVereinigte Staaten
-
Zhujiang HospitalRekrutierungHepatozelluläres Karzinom resezierbarChina
-
Rigshospitalet, DenmarkRekrutierungMagenkrebs | SpeiseröhrenkrebsDänemark
-
Helsinki University Central HospitalInstitute for Molecular MedicineUnbekannt